Edition:
United Kingdom

Smith & Nephew PLC (SN.L)

SN.L on London Stock Exchange

1,276.00GBp
2:07pm BST
Change (% chg)

1.50 (+0.12%)
Prev Close
1,274.50
Open
1,277.50
Day's High
1,281.00
Day's Low
1,265.00
Volume
726,778
Avg. Vol
2,191,595
52-wk High
1,442.00
52-wk Low
1,173.00

Select another date:

Thu, Jul 26 2018

Smith & Nephew buoyed by recovery in U.S. market

LONDON Smith & Nephew's new chief executive confirmed the company's full-year guidance on Thursday after improvement in its U.S. market helped revenues for the artificial hip and knee maker to recover from a tough start to the year.

Smith & Nephew sticks to full-year view as established markets recover

LONDON, July 26 Smith & Nephew, Europe's biggest artificial hip and knee maker, reiterated its full-year guidance on Thursday after its established markets returned to growth after a difficult start to the year.

Smith & Nephew, financials knock FTSE off three-month high

LONDON Britain's top share index slipped on Thursday as a tumble in Smith & Nephew's shares and weakness across financials and health stocks dragged the FTSE 100 off a three-month high.

UPDATE 1-Smith & Nephew, financials knock FTSE off 3-month high

* Trade war worries weigh on global markets (Recasts, updates prices at close)

Outgoing Smith & Nephew CEO signs off with a downgrade

LONDON Smith & Nephew downgraded its revenue and profit forecasts after a weak first quarter on Thursday, days before Chief Executive Olivier Bohuon will end his seven-year tenure at the artificial knee and hip maker.

UPDATE 2-Outgoing Smith & Nephew CEO signs off with a downgrade

* Shares fall 7 pct (Adds CEO comments, analyst reaction, shares)

BRIEF-Smith & Nephew CEO says trend already improving

* CEO SAYS DECLINE IN ESTABLISHED MARKETS WAS MAINLY DUE TO MARKET WEAKNESS

Smith & Nephew downgrades outlook after weak Q1

LONDON, May 3 Smith & Nephew, Europe's biggest artificial hip and knee maker, downgraded its forecast for full-year underlying revenue growth and profit margin after some markets softened and it saw a slowdown in its bioactives business in the first quarter.

Select another date: